Spots Global Cancer Trial Database for veliparib
Every month we try and update this database with for veliparib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT01642251 | Extensive Stage... Large Cell Lung... Neuroendocrine ... Small Cell Carc... Stage IV Non-Sm... | Cisplatin Etoposide Veliparib Placebo | 18 Years - | National Cancer Institute (NCI) | |
| ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00770471 | Brain and Centr... | temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | NCT01154426 | Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ... | Diagnostic Labo... Gemcitabine Hyd... Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer | NCT01477489 | Breast Cancer | Veliparib Standard radiat... | 19 Years - | University of Michigan Rogel Cancer Center | |
| To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | NCT01199224 | Solid Tumors | veliparib veliparib veliparib veliparib | 18 Years - | AbbVie | |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | NCT01366144 | Breast Carcinom... Carcinoma of Un... Endometrial Car... Esophageal Carc... Liver Failure Lung Carcinoma Malignant Head ... Malignant Testi... Melanoma Metastatic Mali... Ovarian Carcino... Renal Failure Unresectable Ma... Urothelial Carc... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01576172 | Castration-Resi... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Prednisone Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | NCT00989651 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Carcino... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Stage IIA Fallo... Stage IIA Ovari... Stage IIB Fallo... Stage IIB Ovari... Stage IIC Fallo... Stage IIC Ovari... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Bevacizumab Carboplatin Cisplatin Laboratory Biom... Paclitaxel Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | NCT01017640 | Solid Neoplasm | Laboratory Biom... Mitomycin Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer | NCT01657799 | Brain Metastase... | Veliparib Placebo Whole brain rad... | 18 Years - 99 Years | AbbVie | |
| A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | NCT02033551 | Breast Cancer Ovarian Cancer Colon Cancer Lung Cancer Gastric Cancer Solid Tumors | Veliparib Carboplatin Paclitaxel FOLFIRI | 18 Years - 99 Years | AbbVie | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01576172 | Castration-Resi... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Prednisone Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | NCT00588991 | Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Chronic Myeloid... Chronic Myelomo... de Novo Myelody... Essential Throm... Hematopoietic a... Myelodysplastic... Polycythemia Ve... Recurrent Adult... Recurrent Adult... Secondary Myelo... | Carboplatin Laboratory Biom... Topotecan Hydro... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | NCT02831179 | Functional Panc... Malignant Somat... Merkel Cell Car... Metastatic Adre... Metastatic Carc... Multiple Endocr... Multiple Endocr... Multiple Endocr... Neuroendocrine ... Non-Functional ... Pancreatic Gluc... Pancreatic Insu... Recurrent Adren... Recurrent Adren... Recurrent Merke... Somatostatin-Pr... Stage III Adren... Stage III Thyro... Stage IIIA Merk... Stage IIIB Merk... Stage IV Adrena... Stage IV Merkel... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thymic Carcinoi... VIP-Producing N... Well Differenti... Zollinger Ellis... | Capecitabine Temozolomide Veliparib Pharmacological... Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | NCT01589419 | Locally Advance... | veliparib capecitabine radiation | 18 Years - 99 Years | AbbVie | |
| Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01540565 | BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Epithel... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 | Ovarian Cancer | veliparib carboplatin paclitaxel | 20 Years - 99 Years | AbbVie | |
| MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | NCT01827384 | Advanced Malign... | Adavosertib Carboplatin Everolimus Temozolomide Trametinib Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation | NCT01472783 | Recurrent, Epit... | Veliparib | 18 Years - | Vejle Hospital | |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT02412371 | Non-small Cell ... | Paclitaxel Placebo for Vel... Carboplatin Veliparib Radiotherapy | 18 Years - | AbbVie | |
| Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | NCT02985658 | Metastatic Brea... Triple-Negative... | Veliparib Cisplatin Vinorelbine | 18 Years - | University of Washington | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | NCT00740805 | Ann Arbor Stage... Ann Arbor Stage... Solid Neoplasm | Cyclophosphamid... Doxorubicin Hyd... Laboratory Biom... Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Expanded Access to Veliparib | NCT03123211 | Solid Tumors Wi... Triple Negative... High Grade Sero... Patients Requir... | Veliparib | - | AbbVie | |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | NCT01818063 | Estrogen Recept... HER2-negative B... Progesterone Re... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | Paclitaxel Carboplatin Doxorubicin Cyclophosphamid... Veliparib | 18 Years - | Thomas Jefferson University | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| Study in Patients With SCLC of Veliparib in Combination With Topotecan | NCT03227016 | Small Cell Lung... | veliparib Topotecan | 18 Years - 85 Years | Central European Society for Anticancer Drug Research | |
| To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors | NCT01193140 | Solid Tumor Can... | veliparib Temozolomide | 18 Years - | Abbott | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | NCT01638546 | Recurrent Small... | Laboratory Biom... Placebo Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | NCT02595905 | Metastatic BRCA... Metastatic Brea... Metastatic Mali... Metastatic Trip... Recurrent Breas... Stage IV Breast... | Cisplatin Laboratory Biom... Placebo Adminis... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01585805 | Locally Advance... Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Gemcitabine Gemcitabine Hyd... Magnetic Resona... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | NCT01638546 | Recurrent Small... | Laboratory Biom... Placebo Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| Study in Patients With SCLC of Veliparib in Combination With Topotecan | NCT03227016 | Small Cell Lung... | veliparib Topotecan | 18 Years - 85 Years | Central European Society for Anticancer Drug Research | |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT01386385 | Lung Adenocarci... Lung Adenocarci... Lung Large Cell... Lung Squamous C... Minimally Invas... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... | 3-Dimensional C... Carboplatin Laboratory Biom... Paclitaxel Placebo Adminis... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | NCT01264432 | Adult Solid Neo... Peritoneal Carc... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... Quality-of-Life... Radiation Thera... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor | NCT01123876 | Gastric Cancer | Veliparib | 18 Years - 99 Years | AbbVie | |
| Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | NCT01266447 | Cervical Adenoc... Cervical Adenos... Cervical Small ... Cervical Squamo... Recurrent Cervi... Stage III Cervi... Stage IVA Cervi... Stage IVB Cervi... | Filgrastim Laboratory Biom... Pegfilgrastim Topotecan Hydro... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01585805 | Locally Advance... Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Gemcitabine Gemcitabine Hyd... Magnetic Resona... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia | NCT01139970 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult B Acute L... Adult B Acute L... Adult T Acute L... Alkylating Agen... Chronic Myelomo... Recurrent Adult... Recurrent Adult... Secondary Acute... | Laboratory Biom... Pharmacological... Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer | NCT01908478 | Pancreatic Canc... | Veliparib Gemcitabine Intensity modul... | 18 Years - | Cedars-Sinai Medical Center | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes | NCT03061188 | Advanced Solid ... Aggressive Non-... Recurrent Solid... Refractory Mant... T-Cell Non-Hodg... Unresectable So... | Laboratory Biom... Nivolumab Pharmacological... Veliparib | 18 Years - | Northwestern University | |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | NCT02305758 | Untreated Metas... | Veliparib Placebo Modified FOLFIR... FOLFIRI Bevacizumab Fluorouracil in... | 18 Years - 99 Years | AbbVie | |
| Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | NCT01351909 | Locally Advance... Metastatic Brea... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Cyclophosphamid... Laboratory Biom... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | NCT01853306 | Oncology BRCA Mutated High Grade Sero... BRCA Mutated Br... | Veliparib | 18 Years - 99 Years | AbbVie | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT01459380 | Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... | Bevacizumab Carboplatin Laboratory Biom... Pegylated Lipos... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02152982 | Glioblastoma Gliosarcoma | Laboratory Biom... Placebo Adminis... Quality-of-Life... Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | NCT01818063 | Estrogen Recept... HER2-negative B... Progesterone Re... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | Paclitaxel Carboplatin Doxorubicin Cyclophosphamid... Veliparib | 18 Years - | Thomas Jefferson University | |
| Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | NCT01017640 | Solid Neoplasm | Laboratory Biom... Mitomycin Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | NCT00535119 | Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ... Hereditary Brea... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | NCT01560104 | Non-Small -Cell... | Veliparib Carboplatin paclitaxel placebo | 18 Years - 99 Years | AbbVie | |
| Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | NCT01281852 | Cervical Adenoc... Cervical Adenos... Cervical Squamo... Recurrent Cervi... Stage IVB Cervi... | Cisplatin Laboratory Biom... Paclitaxel Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT01459380 | Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... | Bevacizumab Carboplatin Laboratory Biom... Pegylated Lipos... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | NCT01690598 | Ovarian Cancer | Veliparib Topotecan | 18 Years - | Vejle Hospital | |
| Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | NCT01506609 | Metastatic Brea... | Placebo Veliparib Carboplatin Temozolomide Paclitaxel | 18 Years - | AbbVie | |
| ABT-888 and Temozolomide for Liver Cancer | NCT01205828 | Hepatocellular ... | Temozolomide ABT-888 | 18 Years - | Georgetown University | |
| Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | NCT02921256 | Rectal Adenocar... Stage II Rectal... Stage III Recta... | Capecitabine Fluorouracil Intensity-Modul... Leucovorin Oxaliplatin Pembrolizumab Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | NCT01366144 | Breast Carcinom... Carcinoma of Un... Endometrial Car... Esophageal Carc... Liver Failure Lung Carcinoma Malignant Head ... Malignant Testi... Melanoma Metastatic Mali... Ovarian Carcino... Renal Failure Unresectable Ma... Urothelial Carc... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer | NCT01477489 | Breast Cancer | Veliparib Standard radiat... | 19 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | NCT01853306 | Oncology BRCA Mutated High Grade Sero... BRCA Mutated Br... | Veliparib | 18 Years - 99 Years | AbbVie | |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02470585 | Ovarian Cancer Ovarian Neoplas... | Veliparib Paclitaxel Carboplatin Placebo to Veli... | 18 Years - | AbbVie | |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | NCT02831179 | Functional Panc... Malignant Somat... Merkel Cell Car... Metastatic Adre... Metastatic Carc... Multiple Endocr... Multiple Endocr... Multiple Endocr... Neuroendocrine ... Non-Functional ... Pancreatic Gluc... Pancreatic Insu... Recurrent Adren... Recurrent Adren... Recurrent Merke... Somatostatin-Pr... Stage III Adren... Stage III Thyro... Stage IIIA Merk... Stage IIIB Merk... Stage IV Adrena... Stage IV Merkel... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thymic Carcinoi... VIP-Producing N... Well Differenti... Zollinger Ellis... | Capecitabine Temozolomide Veliparib Pharmacological... Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | NCT02158507 | Metastatic Trip... | Combination of ... | 19 Years - | University of Alabama at Birmingham | |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia | NCT01139970 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult B Acute L... Adult B Acute L... Adult T Acute L... Alkylating Agen... Chronic Myelomo... Recurrent Adult... Recurrent Adult... Secondary Acute... | Laboratory Biom... Pharmacological... Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | NCT01711541 | Head and Neck S... Stage IVA Oroph... Stage IVB Oroph... | Carboplatin Cisplatin Fluorouracil Hydroxyurea Laboratory Biom... Paclitaxel Placebo Adminis... Radiation Thera... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT02944396 | Non-Small Cell ... | pemetrexed nivolumab paclitaxel veliparib carboplatin | 18 Years - | AbbVie | |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01576172 | Castration-Resi... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Prednisone Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia | NCT01139970 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult B Acute L... Adult B Acute L... Adult T Acute L... Alkylating Agen... Chronic Myelomo... Recurrent Adult... Recurrent Adult... Secondary Acute... | Laboratory Biom... Pharmacological... Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | NCT01711541 | Head and Neck S... Stage IVA Oroph... Stage IVB Oroph... | Carboplatin Cisplatin Fluorouracil Hydroxyurea Laboratory Biom... Paclitaxel Placebo Adminis... Radiation Thera... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | NCT03581292 | Anaplastic Astr... Glioblastoma Malignant Gliom... | Radiation Thera... Temozolomide Veliparib | 3 Years - 25 Years | National Cancer Institute (NCI) | |
| Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | NCT01749397 | Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Floxuridine Laboratory Biom... Pharmacological... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer | NCT01489865 | Metastatic Panc... | ABT-888 and mFO... | 18 Years - | Georgetown University | |
| Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer | NCT01149083 | Anatomic Stage ... Anatomic Stage ... Locally Advance... Metastatic Brea... Unresectable Br... | Biopsy Biospecimen Col... Carboplatin Computed Tomogr... Magnetic Resona... Veliparib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
